Expert Analysis

Special Hepatic Issues and Populations

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Special Hepatic Issues and Populations

Faculty:
Robert J. Fontana, MD Stephen A. Harrison, MD, LTC, MC David L. Thomas, MD, MPH

CME CREDIT INFORMATION

Release Date: 01/14/08

Expiration Date: 01/13/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.3 contact hours (0.13 CEUs)

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe data regarding the management of patients undergoing liver transplantation for viral hepatitis
Discuss recent studies regarding the risk factors for the development of hepatocellular carcinoma
Specify the latest data on the management of hepatitis in the injection drug user population
Assess factors that attribute to the progression of chronic liver disease

Topics covered include:

Management of Liver Transplantation Recipients Infected With HBV
Management of HCV-Infected Recipients Receiving Liver Transplantation
HCV Infection Risk Factors for the Development of Hepatocellular Carcinoma
Use of Prophylactic Lamivudine Therapy to Inhibit HBV Reactivation During Chemotherapy
Clinical Findings Concerning the Management of HCV/HIV Coinfection
Management of HCV-Infected Patients in the Methadone Maintenance Setting
The Role of Insulin Resistance and Diabetes in HCV Infection
Clinical Findings Concerning the Management of Steatosis

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.